Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: A case-control study

Antimicrobial Resistance and Infection Control

Volumn 6, Issue 1, 2017, Pages

  Harris, Patrick N A ^a   Peri, Anna M ^b   Pelecanos, Anita M ^c   Hughes, Carly M ^d   Paterson, David L ^a,e   Ferguson, John K ^d,f,g  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MILAN   (Italy)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e Wesley Research Institute   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g UNIVERSITY OF NEW ENGLAND   (Australia)

Author keywords

AmpC; Bacteraemia; Beta lactamase; Enterobacter aerogenes; Enterobacter cloacae; Outcomes; Relapse; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TRIMETHOPRIM;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BLOOD CULTURE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NONHUMAN; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

EID: 85009977192     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/s13756-017-0177-0     Document Type: Article

References (36)

1. Mezzatesta ML, Gona F, Stefani S. Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance. Future Microbiol. 2012;7:887-902.
2. Sanders Jr WE, Sanders CC. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev. 1997;10:220-41.
3. Liu WY, Wong CF, Chung KM, Jiang JW, Leung FC. Comparative genome analysis of Enterobacter cloacae. PLoS One. 2013;8, e74487.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17.
5. Chen HN, Lee ML, Yu WK, Lin YW, Tsao LY. Late-onset Enterobacter cloacae sepsis in very-low-birth-weight neonates: experience in a medical center. Pediatr Neonatol. 2009;50:3-7.
6. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998-2007. Clin Microbiol Infect. 2011;17:539-45.
7. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012;40:297-305.
8. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-90.
9. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001;45:2628-30.
10. Choi SH, Lee JE, Park SJ, Choi SH, Lee SO, Jeong JY, Kim MN, Woo JH, Kim YS. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 2008;52:995-1000.
11. Siebert JD, Thomson Jr RB, Tan JS, Gerson LW. Emergence of antimicrobial resistance in gram-negative bacilli causing bacteremia during therapy. Am J Clin Pathol. 1993;100:47-51.
12. Boyle RJ, Curtis N, Kelly N, Garland SM, Carapetis JR. Clinical implications of inducible beta-lactamase activity in Gram-negative bacteremia in children. Pediatr Infect Dis J. 2002;21:935-40.
13. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162:185-90.
14. Qureshi ZA, Paterson DL, Pakstis DL, Adams-Haduch JM, Sandkovsky G, Sordillo E, Polsky B, Peleg AY, Bhussar MK, Doi Y. Risk factors and outcome of extended-spectrum beta-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents. 2011;37:26-32.
15. Chen CH, Huang CC. Risk factor analysis for extended-spectrum beta-lactamase-producing Enterobacter cloacae bloodstream infections in central Taiwan. BMC Infect Dis. 2013;13:417.
16. Wozniak A, Villagra NA, Undabarrena A, Gallardo N, Keller N, Moraga M, Roman JC, Mora GC, Garcia P. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. J Med Microbiol. 2012;61:1270-9.
17. Manzur A, Tubau F, Pujol M, Calatayud L, Dominguez MA, Pena C, Sora M, Gudiol F, Ariza J. Nosocomial outbreak due to extended-spectrum-beta-lactamase- producing Enterobacter cloacae in a cardiothoracic intensive care unit. J Clin Microbiol. 2007;45:2365-9.
18. Chang CL, Su LH, Lu CM, Tai FT, Huang YC, Chang KK. Outbreak of ertapenem-resistant Enterobacter cloacae urinary tract infections due to a contaminated ureteroscope. J Hosp Infect. 2013;85:118-24.
19. Cremet L, Bourigault C, Lepelletier D, Guillouzouic A, Juvin ME, Reynaud A, Corvec S, Caroff N. Nosocomial outbreak of carbapenem-resistant Enterobacter cloacae highlighting the interspecies transferability of the blaOXA-48 gene in the gut flora. J Antimicrob Chemother. 2012;67:1041-3.
20. Fernandez A, Pereira MJ, Suarez JM, Poza M, Trevino M, Villalon P, Saez-Nieto JA, Regueiro BJ, Villanueva R, Bou G. Emergence in Spain of a multidrug-resistant Enterobacter cloacae clinical isolate producing SFO-1 extended-spectrum beta-lactamase. J Clin Microbiol. 2011;49:822-8.
21. Haraoui LP, Levesque S, Lefebvre B, Blanchette R, Tomkinson M, Mataseje L, Mulvey MR, Miller MA. Polyclonal outbreak of KPC-3-producing Enterobacter cloacae at a single hospital in Montreal, Quebec, Canada. J Clin Microbiol. 2013;51:2406-8.
22. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1-12.
23. Siedner MJ, Galar A, Guzman-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, Hooper DC, O'Brien TF, Marty FM. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis. 2014;58:1554-63.
24. Wolff MA, Young CL, Ramphal R. Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. Clin Infect Dis. 1993;16:772-7.
25. Marcos M, Inurrieta A, Soriano A, Martinez JA, Almela M, Marco F, Mensa J. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother. 2008;62:397-403.
26. Le Gall JR, Neumann A, Hemery F, Bleriot JP, Fulgencio JP, Garrigues B, Gouzes C, Lepage E, Moine P, Villers D. Mortality prediction using SAPS II: an update for French intensive care units. Crit Care. 2005;9:R645-652.
27. Implementation Guide for Surveillance of Central Line Associated Bloodstream Infection [http://www.safetyandquality.gov.au/wp-content/uploads/2012/02/Implementation-guide-CLABSI-Consultation-Edition-November-2011.pdf]. Accessed Nov 2016.
28. Auricht E, Borgert J, Butler M, Cadwallader H, Collignon P, Cooper C, Eades M, Ferguson J, Kampen R, Looke D, et al. Uniform national denominator definitions for infection control clinical indicators: surgical site and health care associated blood stream infection. Aust Infect Control. 2001;6:47-53.
29. CDC/NHSN Surveillance Definitions for Specific Types of Infections [http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf]. Accessed Nov 2016.
30. Antibiotic Expert Groups: Therapeutic guidelines: antibiotic. Version 15. Melbourne: Therapeutic Guidelines Limited; 2014.
31. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. In: CLSI document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
32. Breakpoint tables for interpretation of MICs and zone diameters version 5.0 [http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents]. Accessed Nov 2015.
33. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161-82.
34. Harris PN, Alder L, Paterson DL. Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice? Pathology. 2015;47:386-8.
35. Hombach M, Wolfensberger A, Kuster SP, Bottger EC. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. J Clin Microbiol. 2013;51:2385-7.
36. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance [http://www.eucast.org/resistance:mechanisms/]. Accessed Nov 2016.